An Interview with Dunya Botetzayas, RN, Senior Director of Clinical Monitoring at Veristat
At Veristat our need to manage and work in virtual environments continues to increase. With six offices globally and nearly 300 employees, we are building teams with members spread out in different physical locations. Our geographically dispersed teams continue to grow with our increasing remote employee population; In fact remote workers are our largest growing population with nearly 30 % of our employees working from their home offices.
Our Challenge: Join the Battle to Beat Rare Cancers
Our Impact: $150K Raised to Support Rare Cancer Research
For a fifth consecutive year, Team Veristat accepted this challenge in the 2019 Boston #cycleforsurvival event! We exceeded our goal of raising $50,000 to support rare cancer research.
As a Talent Acquisition Consultant for Veristat, I receive many cover letters and resumes from candidates each day. I am often blown away by the experience, knowledge, and expertise of these individuals and always hope to match their skill sets to one of our current openings.
The Food and Drug Administration (FDA) has started encouraging the use of adaptive designs for clinical studies. In essence, adaptive designs allow prospectively planned modifications to a clinical trial based on interim data, provided scientific validity (the ability to draw sound inferences) and data integrity (credibility and reproducibility) are preserved.
Understanding Why Creative Data Collection Solutions Are Necessary
A Recap of the New York Medidata NEXT Event: Where Science Meets Technology Meets the Future
Kathleen Boruchowski, Associate Director of Data Management, attended the Medidata NEXTconference in New York City on November 8-10. The conference, which has many global locations throughout the year, offered Medidata’s customers a front row seat to learn how data, insights, and technology are transforming the clinical trials industry and ultimately accelerating the hope for patients desperately seeking new treatment options.
In pharmaceutical clinical trials, considering competing risk analyses is highly important. Competing risks are events that may occur and prevent the evaluation of a specific primary endpoint, in turn biasing risk estimations or drug efficacy.
To Improve Real-Time Visibility of Clinical Trial Documentation and Inspection-Readiness
Veristat has completed the validation and configuration of Master Control’s eTMF system, which is now implemented and available for Veristat managed clinical trials.